Infinity Pharmaceuticals EBITDA 2010-2023 | INFIQ

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Infinity Pharmaceuticals ebitda from 2010 to 2023. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Infinity Pharmaceuticals ebitda from 2010 to 2023. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$81.3B
Zoetis (ZTS)	$67.2B
Daiichi Sankyo, - (DSNKY)	$46.3B
Takeda Pharmaceutical (TAK)	$45.6B
BeOne Medicines - (ONC)	$33.5B
Sandoz Group AG (SDZNY)	$26B
Summit Therapeutics (SMMT)	$19.9B
Merck (MKKGY)	$16.9B
Shionogi (SGIOY)	$14.3B
United Therapeutics (UTHR)	$13.4B
Neurocrine Biosciences (NBIX)	$13.3B
Orion OYJ (ORINY)	$11.4B
IPSEN (IPSEY)	$10.8B
Stevanato Group S.p.A (STVN)	$7.7B
Corcept Therapeutics (CORT)	$7.2B
Grifols, S.A (GRFS)	$7.2B
Ionis Pharmaceuticals (IONS)	$6.6B
Madrigal Pharmaceuticals (MDGL)	$6.5B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.2B
Hypermarcas (HYPMY)	$3B
Crinetics Pharmaceuticals (CRNX)	$2.7B
Catalyst Pharmaceuticals (CPRX)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2B
Ocular Therapeutix (OCUL)	$1.9B
Endo (NDOI)	$1.8B
ARS Pharmaceuticals (SPRY)	$1.7B